Peptide LC-MS Carryover: When the Previous Sample Appears in the Next Run
A small residual peak can be an instrument memory effect—not necessarily a constituent of the research sample. Understanding carryover is essential for interpreting peptide chromatography and certificates of analysis.
Liquid chromatography–mass spectrometry (LC-MS) is a powerful tool for investigating peptide identity and related substances. Yet an instrument can retain traces of an earlier injection and release them during a later run. This phenomenon, known as sample carryover, creates an analytical question: did a detected signal originate from the current specimen, or from material remaining in the analytical pathway?
For researchers comparing peptide batches, assessing chromatographic purity or reviewing a certificate of analysis (COA), that distinction matters. Carryover is not the same as sample contamination, ion suppression, or peptide degradation. It is a potential source of misleading signals introduced by the measurement process itself.
What is peptide carryover in LC-MS?
Carryover occurs when analyte from one injection persists in an autosampler, tubing, valve, column or other wetted component and is detected in a subsequent injection. Peptides can interact with surfaces through hydrophobic, electrostatic and other interactions. Depending on the molecule and the instrument, residues may be released gradually. A blank injection after a concentrated sample may therefore show a peak at the same retention time and mass-to-charge ratio as the previous analyte.
Why peptide chemistry can make carryover challenging
Peptides vary substantially in charge, hydrophobicity, chain length and conformation. These properties influence retention on stationary phases and unintended interactions with metal, polymer or other surfaces. Strong chromatographic retention is useful for separating compounds, but excessive or poorly reversible binding can also complicate recovery. A method that works for one peptide cannot automatically be assumed to eliminate carryover for another.
Where residual material may remain
The autosampler needle and needle seat, injection loop, switching valves, guard column, analytical column and connecting flow path are all potential contributors. In a published investigation involving neuropeptide Y, researchers systematically isolated instrument components and identified contributions from the column—particularly the guard column—and from needle and valve seals. This illustrates why carryover troubleshooting should be evidence-led rather than reduced to a single generic washing instruction.
How researchers distinguish carryover from a real impurity
A useful diagnostic sequence includes a suitable blank immediately after a high-concentration sample, comparison with blanks placed elsewhere in the sequence, and assessment of whether the residual peak declines over subsequent blanks. The analyst examines retention time, relevant mass transitions or spectra, and the magnitude of the signal relative to the method’s validated limits. A peak in a blank is a warning that the system may contribute to the next measurement; it does not by itself prove the following sample is contaminated.
A blank following a high-level sample is particularly informative. A clean solvent blank before the sequence alone cannot establish that later injections are free of memory effects.
Carryover versus adsorption versus matrix effects
These problems can overlap but are not interchangeable. Adsorption can reduce the amount of peptide recovered from a sample container or analytical flow path; carryover involves delayed release into later injections. Matrix effects, by contrast, alter the efficiency of ion formation or detection and can suppress or enhance LC-MS signal without changing the true analyte amount. A laboratory can therefore encounter low recovery, misleading extra peaks and distorted quantification for different reasons. Read our related articles on peptide adsorption to glass and plastic and LC-MS matrix effects and ion suppression.
What the published literature shows
Mitulović and colleagues reported that peptide and protein carryover can persist in nano-LC-MS workflows and evaluated cleaning approaches targeting the injection path, trap column and separation column. Their findings support the general principle that carryover must be measured and addressed at the method level. A separate investigation using neuropeptide Y demonstrated the value of systematically identifying affected components. Neither study establishes a universal wash solvent, universal acceptable carryover threshold or one-size-fits-all peptide testing protocol.
Why validated methods and acceptance criteria matter
A credible analytical procedure defines its intended purpose and establishes suitable performance characteristics. The ICH Q2(R2) framework discusses specificity, accuracy, precision, range and other validation considerations. Its regulatory scope concerns analytical procedures for medicinal products; it is useful scientific context for research laboratories, but should not be misrepresented as a certification of any particular research-use peptide product. Carryover limits and blank acceptance criteria should be justified for the actual method, concentration range and decision being made.
How carryover affects interpretation of a peptide COA
A COA is a record of reported testing, not a guarantee that every conceivable source of analytical error has been excluded. When interpreting a peptide COA, consider whether the document identifies the test method, sample and batch; whether identity and purity claims are supported by appropriate evidence; and whether the laboratory’s quality system includes system suitability, blanks and controls. A chromatogram alone cannot show the entire injection sequence. Our Research Peptides UK – Complete Guide explains the broader context of research sourcing and quality assessment, while the COA Library provides access to available batch documentation.
Practical questions for laboratory researchers
Was a blank injected after a concentrated standard or sample? Did the suspected signal appear at the expected retention time and in relevant mass channels? Was carryover assessed across the intended concentration range? Did the laboratory document appropriate acceptance criteria? Could the peak arise from a genuine related substance, laboratory contamination, or another analytical interference instead? These questions help separate observation from conclusion.
Why a low-level peak should not be overinterpreted
Small signals near detection or quantitation limits require particular caution. A trace peak may be analytically detectable without being reliably quantifiable. Background, integration settings, noise and the sequence of preceding injections all influence interpretation. Equally, the absence of a visible peak in a published image does not establish that a method has been fully validated. Researchers should request sufficient methodological context before drawing strong conclusions.
The wider lesson for peptide research
The reliability of peptide analysis depends on more than a sophisticated instrument. Sample handling, chromatography, detection, sequence design, blank controls and method validation all shape the final result. Carryover is a reminder that an analytical measurement is produced by an entire workflow. A defensible interpretation distinguishes what was actually measured from what the evidence can reasonably establish.
Scientific references
- Mitulović G et al. Preventing carryover of peptides and proteins in nano LC-MS separations. Analytical Chemistry (2009). DOI: 10.1021/ac900696m.
- Troubleshooting Carry-Over in the LC-MS Analysis of Biomolecules: The Case of Neuropeptide Y. Full-text research article.
- Murphy et al. Improved intact peptide and protein quantitation by LC-MS: Battling the deleterious effects of analyte adsorption. Analytical Science Advances (2021). DOI: 10.1002/ansa.202000102.
- European Medicines Agency. ICH Q2(R2): Validation of Analytical Procedures. Effective 14 June 2024. Guideline.
This article is provided by 24hour Peptides for scientific education and laboratory research information only. Research-use-only materials are not intended for human or veterinary administration, diagnosis, treatment or consumption. References to analytical procedures do not establish suitability for clinical use, sterility or safety.
